Lumiliximab
- Generic Name
- Lumiliximab
- Drug Type
- Biotech
- CAS Number
- 357613-86-6
- Unique Ingredient Identifier
- 8Z13S29R5A
- Background
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.
- Indication
Investigated for use/treatment in asthma and leukemia (lymphoid).
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCR
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 40
- Registration Number
- NCT00801060
- Locations
- 🇺🇸
University of Florida/Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Vanderbilt University Medical Center-IPF Program, Nashville, Tennessee, United States
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: FCR
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 627
- Registration Number
- NCT00391066
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2005-02-11
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 31
- Registration Number
- NCT00103558
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.